Nivolumab
- Generic Name
- Nivolumab
- Brand Names
- Opdivo, Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 946414-94-4
- Unique Ingredient Identifier
- 31YO63LBSN
- Background
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...
- Indication
Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...
- Associated Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- Complete Surgical Resection, Neoadjuvant Therapies
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 57
- Registration Number
- NCT02453620
- Locations
- 🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 76
- Registration Number
- NCT02451982
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 19
- Registration Number
- NCT02446860
- Locations
- 🇬🇧
The Royal Marsden NHS Foundation Trust, London, United Kingdom
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Heat Biologics
- Target Recruit Count
- 121
- Registration Number
- NCT02439450
- Locations
- 🇺🇸
UC San Diego, La Jolla, California, United States
🇺🇸Horizon Oncology Research, Lafayette, Indiana, United States
🇺🇸Ashland-Bellefonte Cancer Center, Ashland, Kentucky, United States
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 94
- Registration Number
- NCT02434081
- Locations
- 🇨🇭
HFR Fribourg- Hôpital cantonal, Fribourg, Switzerland
🇳🇱VUMC, Amsterdam, Netherlands
🇨🇭Kantonsspital Winterthur, Winterthur, Switzerland
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT02428192
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT02426892
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 41
- Registration Number
- NCT02423343
- Locations
- 🇺🇸
H Lee Moffitt Cancer Center, Tampa, Florida, United States
🇪🇸Hospital Regional Universitario de Málaga, Malaga, Spain
🇪🇸Institut Catala d'Oncologia, Barcelona, Spain
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT02423954
- Locations
- 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Conditions
- Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Fallopian Tube CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell CarcinomaOvarian CarcinomaPathologic Stage III Cutaneous Melanoma AJCC V8
- Interventions
- Drug: CarboplatinDrug: EribulinDrug: FluorouracilDrug: PaclitaxelDrug: CyclophosphamideDrug: CapecitabineBiological: PembrolizumabDrug: OlaparibBiological: NivolumabBiological: IpilimumabDrug: SelinexorDrug: DoxorubicinDrug: TopotecanDrug: PemetrexedDrug: Irinotecan HydrochlorideDrug: OxaliplatinDrug: Leucovorin Calcium
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 221
- Registration Number
- NCT02419495
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.